华瞻素胶囊联合多西他塞治疗乳腺癌的临床观察

Clinical Observation on Cinobufotalin Capsule combined with Docetaxel in Treatment of Breast Cancer

目的:探讨华瞻素胶囊联合多西他塞治疗乳腺癌的临床疗效。方法:选取乳腺癌术后患者50例,按照随机数字表法随机分成对照组和观察组,每组25例。对照组患者予以多西他塞治疗,而观察组患者在予以多西他塞治疗的基础上联合华瞻素胶囊药物口服治疗。治疗6周后分别对两组患者的临床疗效、血常规、生活质量以及不良反应发生情况进行比较。结果:①观察组的总治疗有效率为96.00%,显著高于对照组的治疗有效率76.00%,差异有统计学意义(χ^2=4.410;P=0.036);②观察组患者的血小板计数(PLT)减少、血红细胞(HGB)减少以及白细胞(WBC)减少发生率均显著低于对照组患者,差异有统计学意义(χ^2=10.083、9.742、9.934;P=0.001、0.005、0.002);③患者的生活质量水平明显高于对照组患者,差异有统计学意义(t=3.977、2.537、2.344、2.311、6.762、3.767;P<0.05);④观察组患者的不良反应发生率为12.00%,显著低于对照组患者的不良反应发生率40.00%,差异有统计学意义(χ^2=5.094;P=0.024)。结论:采用华瞻素胶囊联合多西他塞对乳腺癌术后患者进行化疗,能够有效减少药物不良反应的发生,提高患者的临床疗效,明显改善生活质量,值得临床上广泛推广。

Objective:To explore the clinical effect of breast cancer treated with Cinobufotalin Capsule combined with docetaxel. Methods:50 patients with breast cancer after operation were randomly divided into control group and observation group, 25 cases in each group. Patients in the control group were given docetaxel treatment, while those in the observation group were given docetaxel treatment on the basis of the combination of oral Cinobufotalin Capsule. After 6 weeks intervention, the clinical efficacy, blood routine, quality of life and adverse reactions were compared between the two groups. Results:①The total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group(76.00%)(χ^2=4.410;P=0.036).②The incidence of platelet count(PLT), erythrocyte count(HGB) and leukopenia(WBC) in the observation group were significantly lower than those in the control group(χ^2=10.083,9.742,9.934;P=0.001,0.005,0.002).③The quality of life of the patients was significantly higher than that of the control group(t=3.977,2.537,2.344,2.311,6.762,3.767,P<0.05).④The incidence of adverse reactions in observation group was 12.00%, which was significantly lower than that in control group(40.00%)(χ^2=5.094;P=0.024). Conclusion:Cinobufotalin Capsule combined with docetaxel in the chemotherapy of postoperative breast cancer patients can effectively reduce the occurrence of drug toxicity and side effects, improve the clinical efficacy of patients and significantly improve the quality of life, worthy of clinical promotion.